What is Silence Therapeutics PLC?
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.23B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.